ESTRO 2024 - Abstract Book

S790

Clinical - CNS

ESTRO 2024

Overall survival (OS), local relapse-free survival (LRFS), distant relapse-free survival (DRFS) and radionecrosis-free survival (RNFS) were the endpoints assessed using the Kaplan-Meier product limit method. Age, gender, GTV, WHO grade, and PT timing (primary treatment vs recurrence) were evaluated as prognostic variables for outcome endpoints.

Results:

Thirteen patients (7.4%) developed local tumor progression after a median time of 41 months. Among these cases, 11 had non-benign meningiomas, and 1 had hemangiopericytoma (WHO II-III).

Kaplan-Meier survival curves are reported in Image2.